X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4B (PDE4B) inhibitor prodrug. It is being evaluated in preclinical studies for the treatment of moderate-to-severe ulcerative colitis.
Lead Product(s): PALI-2108
Therapeutic Area: Gastroenterology Product Name: PALI-2108
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
Under the agreement, Palisade wil develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform, including GT-2108, an orally administered, gut-restricted, colon-specific PDE4 inhibitor prodrug in development for patients affected by ulcerative colitis.
Lead Product(s): GT-2108
Therapeutic Area: Gastroenterology Product Name: GT-2108
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Giiant pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 06, 2023
Details:
LB1148 (tranexamic acid) is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: LB1148
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
LB1148 (tranexamic acid) is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
LB1148 (tranexamic acid), is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
LB1148 (tranexamic acid), is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
LB1148 (tranexamic Acid), is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
LB1148 (tranexamic acid) is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. It is being investigated to accelerate the return of bowel function following abdominal surgery.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newsoara Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
In clinical studies, LB1148 (tranexamic acid) has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2022
Details:
The oral presentation will include new GI functional data sub-cuts from highly statistically significant Phase 2 clinical study demonstrating LB1148 (tranexamic acid) accelerated the return of post-operative GI function in patients undergoing elective bowel resection.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
